Bcr-Abl

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

Bcr-Abl

Bcr-Abl related products

Cat No.	Product Name	CAS No.	Product Description
V0680	Degrasyn (WP-1130)	856243-80-6	Degrasyn (formerly also known as WP1130) is a novel, potent, and selective small molecule inhibitor of deubiquitinases (DUBs such as USP5, USP14, USP9x, UCH-L1, and UCH37).
V0678	GNF-2	778270-11-4	GNF-2 (GNF 2; GNF2) is a highly potent, selective and allosteric/non-ATP competitive inhibitor of Bcr-Abl with potential anticancer activity.
V0674	GNF-5	778277-15-9	GNF-5 (GNF 5; GNF5), aGNF-2 analog with better pharmacokinetic profiles, is a potent,selective and allosteric/non-ATP competitive Bcr-Abl inhibitor with potential anticancer activity.
V0672	GNF-7	839706-07-9	GNF-7 (GNF7; GNF 7) is a novel, potent, orally bioactive/bioavailable Bcr-Abl kinase inhibitor with potential anticancer activity.
V0676	PD173955	260415-63-2	PD173955 (PD-173955), asrc-selective tyrosine kinase inhibitor, is a novel and potent Bcr-Abl inhibitor with potential anticancer activity.
V144996	SJ11646	2933135-82-9	SJ11646 is a dasatinib-based LCK PROTAC degrader with a median lethal concentration (DC50) of 0.00838 pM.
V81409	SNIPER(ABL)-015		SNIPER(ABL)-015, which is made up of GNF5 (ABL inhibitor) and MV-1 (IAP ligand) through a linker, can effectively degrade BCR-ABL protein with DC50 of 5μM.
V146693	Tyrosine kinase-IN-9	370854-75-4	Tyrosine kinase-IN-9 is an inhibitor of c-Abl.
V147081	WB-BC-15	309760-28-9	WB-BC-15 is a c-Abl kinase inhibitor.
V0671	Nilotinib (AMN107; Tasigna)	641571-10-0	Nilotinib (formerly also known asAMN-107, AMN107; trade name Tasigna) is a potent, orally bioavailable aminopyrimidine-based Bcr-Abl inhibitor with antineoplastic activity.
V0679	Bafetinib (INNO-406; NS187)	859212-16-1	Bafetinib (formerly INNO406; NS-187),an investigational anticancer drug originally developed by Nippon Shinyaku and later licensed to CytRx, is an orally bioavailable dual Bcr-Abl/Lyn inhibitor with potential antineoplastic activity.
V0673	Radotinib (IY 5511; Supect)	926037-48-1	Radotinib (formerly IY-5511; IY5511; trade name Supect) is a novel, potent,selective, orally bioavailable, and 2nd generationBCR-ABL1 tyrosine kinase inhibitor with potential antineoplastic activity.
V0677	Rebastinib (DCC2036)	1020172-07-9	Rebastinib (formerly also known asDCC-2036), a novel, potent andorally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity, is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50s of 0.8 nM and 4 nM.
V3299	Ponatinib HCl	1114544-31-8	Ponatinib HCl (AP-24534 HCl; Iclusig), the hydrochloride salt ofPonatinib, is an orally bioavailable and multi-targeted kinase inhibitor approved by the US FDA on December 14, 2012 for the treatment of resistant or intolerant CML and Ph+ ALL.
V3720	Dasatinib HCl	854001-07-3	Dasatinib (formerly known as BMS-354825; sold under the brand name Sprycel), is a novel, potent and multi-targeted, orally bioavailable synthetic small molecule inhibitor that targets Abl, Src and c-Kit, with IC50 of<1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
V0629	Dasatinib (BMS354825; Sprycel)	302962-49-8	Dasatinib (formerly known as BMS-354825; sold under the brand name Sprycel), is a novel, potent and multi-targeted, orally bioavailable synthetic small molecule inhibitor that targets Abl, Src and c-Kitwith potential antitumor activity.
V6496	Asciminib HCl	2119669-71-3	Asciminib HCl (ABL001; ABL-001; Scemblix), the hydrochloride salt ofAsciminib,is an allosteric inhibitor of BCR-ABL1 that has been approved FDA on Oct 29th 2021 for treating Philadelphia chromosome-positive CML (chronic myeloid leukemia).
V3183	Asciminib	1492952-76-7	Asciminib (formerly known as ABL-001; ABL001; trade name Scemblix) is a potent and selective allosteric inhibitor of BCR-ABL1 approved in Oct 2021 to treat Philadelphia chromosome-positive CML (chronic myeloid leukemia) with disease that meets certain criteria.